For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Forms of localized treatment have potential to positively impact the survival rate and prognosis of men diagnosed with certain forms of metastatic prostate cancer. Most prostate cancer survivors ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

A new report shows while cancer death rates among Black people are declining, they remain higher than other racial and ethnic ...

Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Real world comparison of time-to-next-treatment (TTNT), ...

Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific ... EBRT and 51% for those undergoing EBRT alone. Additionally, the metastasis-free survival (MFS) rate after 15 ...

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

“Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in ...